B+
Bull case
25%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
ELTX
Elicio TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The planned metastatic-pancreatic-cancer combination study and activated MSK-led neoadjuvant study preserve upside from ELI-002 7P. Reported complete responses following ELI-002 7P and subsequent checkpoint inhibition provide a rationale for further combination testing, but remain preliminary observations rather than controlled efficacy evidence.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +11.7.
What can break
Low coverage and loose peer comparability make external valuation signals unreliable.
Momentum
2
Value
41
Sentiment
49
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.50 · Bull $3.50 · Bear $0.55Analysis 2026-09-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $14.38
Why
Momentum2 · Δ7d +0.0
Value41 · Δ7d -0.1
Sentiment49 · Δ7d +11.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +11.7.
Contradictions & invalidation
- • Low coverage and loose peer comparability make external valuation signals unreliable.
- • Stated cash runway extends only into Q1 2027 despite the July financing, creating material dilution, partnering, and development-continuity risk. [#PR-EARNINGS-2026-08-13]
- • AMPLIFY-7P did not meet its primary endpoint, leaving the company reliant on subgroup analysis and early-stage combination strategies.
Catalyst clock
2026-12-31
Q4 2026 ELI-002 7P combination-trial initiation
Lead driver: Sentiment · See AI snapshot
Momentum
2
8% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
49
45% active weight
Current posture
7d trendImproving
Δ7d
+11.7
Δ21d
-
Why this grade
Composite grade F. Momentum 1.5 / Value 40.6 / Sentiment 49.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-17. Scenario method
Most likely
B
Base case
40%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.55
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$46.06M
Beta
-
Shares Out
27.09M
P/E (TTM) · Derived
-0.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.81
Rev YoY
-100.0%
EPS YoY
-35.1%
Gross Margin
+62.3%
Op Margin
-
Net Debt
-$4.05M
Current Ratio
2.77
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data